Compare Cassava Sciences Inc (FLNA) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs ING Groep NV — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while ING Groep NV trades at $32.81 (market cap $94.33B). The key difference: ING Groep NV is far larger — about 1775.1× Cassava Sciences Inc's market cap, and ING Groep NV pays a 3.8% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | ING | |
|---|---|---|
Market Cap | $53.14M | $94.33B |
Sector | Health | Financials |
52-Week High | $4.64 | $33.31 |
52-Week Low | $1.09 | $22.67 |
Enterprise Value | -$33.43M | — |
Dividend Yield | — | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
ING trades at $32.75, up 1.39% on the day, with a bullish technical signal from moving averages and a neutral RSI. The stock shows solid fundamentals with a P/E of 13.36, net income margin of 27.84%, and a consistent earnings beat history in recent quarters. Recent corporate developments include a new subscription banking model and a dividend announcement for H1-2026.
The outlook is positive with strong analyst support (62.5% Buy rating) and DCF analyses suggesting intrinsic value above current price. Key opportunities include European rate environment benefits and strategic diversification, while risks involve significant negative operating cash flows and sensitivity to macroeconomic conditions affecting the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
